Literature DB >> 10082902

Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections.

W J Martin1, P O Coffin, E Attias, M Balinsky, K Tsou, J M Walker.   

Abstract

Cannabinoids suppress behavioral and neurophysiological responses to noxious stimuli in rodents when administered systemically. The purpose of this study was to extend previous studies of the site of cannabinoid analgesia. Rats were tested in the tail flick test before and after microinjections of the cannabinoid agonist WIN55, 212-2 (5 microg) into one of 17 different brain regions. WIN55,212-2 significantly elevated tail-flick latencies when injected into the amygdala, the lateral posterior and submedius regions of the thalamus, the superior colliculus and the noradrenergic A5 region. By contrast, pain behavior was unaffected by microinjections of the cannabinoid into the other 11 areas examined (prefrontal cortex, nucleus accumbens, lateral hypothalamus, substantia nigra, cuneiform nucleus, anterior pretectal, intralaminar, parafasicular, posterior, thalamic nuclei, as well as the ventral medial, ventral lateral nuclei in the posterior thalamus). Copyright 1999 Published by Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10082902     DOI: 10.1016/s0006-8993(98)01368-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  43 in total

1.  [Endogenous cannabinoid system. Effect on neuronal plasticity and pain memory].

Authors:  S C Azad; V Huge; P Schöps; C Hilf; A Beyer; H-U Dodt; G Rammes; W Zieglgänsberger
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

2.  Metabotropic glutamate and cannabinoid receptor crosstalk in periaqueductal grey pain processing.

Authors:  E Palazzos; V de Novellis; I Marabese; F Rossi; S Maione
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

Review 3.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

4.  Distinct pathways for norepinephrine- and opioid-triggered antinociception from the amygdala.

Authors:  J J Maire; L N Close; M M Heinricher; N R Selden
Journal:  Eur J Pain       Date:  2015-04-05       Impact factor: 3.931

5.  Activation of cannabinoid system in anterior cingulate cortex and orbitofrontal cortex modulates cost-benefit decision making.

Authors:  Abbas Khani; Mojtaba Kermani; Soghra Hesam; Abbas Haghparast; Enrike G Argandoña; Gregor Rainer
Journal:  Psychopharmacology (Berl)       Date:  2014-12-23       Impact factor: 4.530

6.  Effects of GABAA receptors in nucleus cuneiformis on the cannabinoid antinociception using the formalin test.

Authors:  Junjie Chen; Parisa Hasanein; Alireza Komaki; Siamak Yari
Journal:  Psychopharmacology (Berl)       Date:  2021-03-13       Impact factor: 4.530

7.  Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.

Authors:  Kristina B Svendsen; Troels S Jensen; Flemming W Bach
Journal:  BMJ       Date:  2004-07-16

Review 8.  Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.

Authors:  K Rea; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

9.  Migraine: an overview.

Authors:  Salvatore Salomone; Filippo Caraci; Anna Capasso
Journal:  Open Neurol J       Date:  2009-10-01

Review 10.  Dynamic regulation of the endocannabinoid system: implications for analgesia.

Authors:  Devi Rani Sagar; A Gemma Gaw; Bright N Okine; Stephen G Woodhams; Amy Wong; David A Kendall; Victoria Chapman
Journal:  Mol Pain       Date:  2009-10-08       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.